The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Cited by
Items 301–344 of 344
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958 · Cited by 1
Harvey, P. D. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.07.016
Neurophysiological Markers of (Dis)Connectedness: Insights from Ketamine
Alnagger, N., Cardone, P., Montupil, J., Annen, J., Martial, C., Bonhomme, V. L., & Gosseries, O. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_8
Psychedelics: Recent Philosophical Discussions
Letheby, C. (2025) · Springer eBooks · doi:10.1007/978-94-024-2252-8_101
Hepburn, H., Ellenbroek, B. A., & Youn, J. (2025) · Psychedelics · doi:10.1016/j.psyche.2025.100005
Toscano, M. O., Civardi, S. C., & Durbano, F. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1014070
Changing minds: bioethical dimensions of psychedelic-assisted psychotherapy
Jacobs, E. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qq0qxrok6
Psychedelic biomedicalization: mainstreaming a scientific revolution
Neitzke‐Spruill, L. (2023) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/6yb4-rd10 · Cited by 2
Skol Niklasson, E. (2023) · Digitala vetenskapliga arkivet (Diva) (Karlstad University)
Meccia, J. (2023) · eScholarship@McGill (McGill) · doi:10.82308/31606
Persson, A., & Sjöberg, M. (2023) · DiVA (Digitala Vetenskapliga Arkivet)
Noorani, T. N. (2026) · The politics of mental health and illness · doi:10.1007/978-3-032-06313-7_10
Wittenkeller, L. M., Gudelsky, G. G., Winhusen, T. M., & Amato, D. (2026) · Research Square · doi:10.21203/rs.3.rs-8544354/v1
Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience
Lipson, J., Kettner, H., Carhart-Harris, R. L., & Miller, L. (2026) · Behavioral Sciences · doi:10.3390/bs16020310
Trip killers: Addressing a critical knowledge gap in psychedelic research
O’Mahony, B. W., Harrington, C., Harkin, A., & Lally, N. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261431056
“…to mediate therapeutic benefit by facilitating psychological insight, catharsis, and a transient increase in neural and cognitive flexibility (Carhart-Harris and Friston, 2019; Roseman et al., 2018), although direct evidence is lacking (Barbut Siva et al., 2024; Goodwin et al., 2023; Olson, 2020).”
Stellmacher, J., Schmidt, C., Aicher, H., Eichel, K., Brakemeier, E., & Herwig, U. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1771726
“…practiced in this study aligns with perspective 2, but this does not preclude future development of therapeutic applications that emphasize psychedelics ’ psychopharmacological effects (49, 50) or the existential and spiritual dimensions and interpretations sometimes occurring in PAT sessions (51).”
Athéa, H. (2024) · theses.fr (ABES) · doi:10.70675/d1402550z7fe9z4237z90d2z4845d24c1bde · Cited by 1
Keeping an Open Mind About (and With) Psychedelics
Novick, A. M., & Ross, D. A. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.02.009
Gallardo, L. M. (2026) · Preprints.org · doi:10.20944/preprints202604.0415.v1
Secular Mysticism: Entanglements of Science and Religion in Psychedelic Medicine
Seale‐Feldman, A. (2026) · Culture Medicine and Psychiatry · doi:10.1007/s11013-026-09988-x
“…of psychedelics are necessary for therapeutic efficacy, even Olson acknowledges the influence of this theory when he writes that “conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action” (Olson 2021, 563).”
Beyond Description: A Critical Analysis of the Theological Construction of Entheogenic Discourses
Phelps, H. (2026) · Religions · doi:10.3390/rel17050593
Laursen, D. R. T., Salazar, J., Jűrgens, G., & Hróbjartsson, A. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112345
Psühhedeelse taipamisega seotud arvutused ajus
Kaup, K. (2026) · DSpace repository (University of Tartu)
Alterations of consciousness Associated with a Psychedelic Virtual Reality Experience
Kütt, K. R. (2026) · DSpace repository (University of Tartu)
Oña, G., Llagostera, C., Alvarez, O., Dueñas, R. M., González, D., & Soto-Angona, Ó. (2026) · Natural Product Research · doi:10.1080/14786419.2026.2683121
Tobel, T., Cone, A., Choquette, E. M., Garland, M. M., Johnson, M., Mink, K., Lynch, C., Frohlich, J., Feinstein, J. S., Reggente, N., et al. (2026) · Neuroscience of Consciousness · doi:10.1093/nc/niag044
“…reduced psychedelic propensities ( Kaplan et al. 2022), theoretical frameworks suggesting subjective effects may be unnecessary for therapeutic outcomes ( Olson 2021), and case reports of antidepressant responses to psilocybin in the absence of typical psychedelic effects ( Rosenblat et al. 2023).”
Vanderijst, L., Faillie, J., Mura, T., & Luquiens, A. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105423
Ketamine-induced analgesia and dissociation show distinct behavioral and neural correlates
Goldway, N., Jalon, I., Agbaria, Y., Pasternak, Y., Sar-El, R., Mirelman, D., Sarna, N., Green, N., Hendler, T., & Sharon, H. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02496-x
Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation
Chen, H., Ke, B., & Jiang, R. (2026) · Molecules · doi:10.3390/molecules31152611
“A current mechanistic and translational debate in the field centers on whether the intense, altered state of consciousness (the hallucinogenic experience) is a prerequisite for therapeutic efficacy or merely a byproduct of 5-HT2A receptor activation [176,177].”
Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics
Kuypers, K. P. C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1892474
“…consequences of receptor-level engagement rather than a distinct mechanism, and not all individuals who undergo profound or high-intensity psychedelic experiences show clinical improvement, indicating that strong phenomenology alone is insufficient to account for therapeutic outcomes (Olson, 2020).”
ARNISON, C. (2025) · Otago University Research Archive (University of Otago)
A signaling signature distinguishes hallucinogenic from non-hallucinogenic psychedelics
Martin-Guerrero, S. M., Taddei-Tardon, M., Maltman, J. L., Potukanuma, S., González‐Maeso, J., Cutillas, P. R., & López‐Giménez, J. F. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04390-y
Psychedelics as prophylactic neuroprotectants
Maiarù, M. (2026) · Science · doi:10.1126/science.aek3865
Passie, T., & van Elk, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478606
Why taking the trip out of psychedelic medicine is a mistake
Heller, J., & Hendlin, Y. H. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105487
Pobihuszka, D. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00489
Next-Generation Psychedelic Drug Development
Cameron, L. P., Johnson, M. W., Murnane, K. S., Rasenick, M. M., & Nichols, C. D. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00492
Kjellgren, A., Lundberg, J., Yngwe, H., Ekman, C. J., Tiger, M., Ljunglöf, T., Stridh, F., & Beckman, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10879308/v1
Malm, R. (2026) · Journal of Anomalous Experience and Cognition · doi:10.31156/jaex.28663
“…disruptions in predictive coding (Carhart-Harris & Friston, 2019; Vollenweider & Preller, 2020), most research - ers also recognize that psychological factors significantly shape both the therapeutic potential and risks associated with psychedelic use (Carhart-Harris & Friston, 2019; Olson, 2020).”
Ethics of psychedelics in clinical research: a state-of-the-field review
Cheung, K., Jacobs, E., & Yaden, D. B. (2026) · JME Practical Bioethics · doi:10.1136/jmepb-2025-000035
AbouEich, H. K., Izadi, A., Lifshitz, J., Olson, D. E., & Gurkoff, G. G. (2026) · Journal of Neurotrauma · doi:10.1177/08977151261495030
Self-citationPharmacist Guide to Psilocybin and Psychedelic-Assisted Psychotherapy
Vandiver, J. W., Anderson, B. K., Suyama, T. L., & French, A. R. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag388
Metadata
- Authors
- Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Olson, David E.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 563-567
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033607
- OpenAlex
- W3112904824
- Cited by
- 329
- References
- 36
- Citations by year
- 2026: 43 · 2025: 70 · 2024: 69 · 2023: 55 · 2022: 58 · 2021: 31 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (R01GM128997)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- psychedelics, subjective effects, mystical experience, mood, behavior, neuroplasticity, neuropsychiatric disorders, psychedelic medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.